BeautyHealth’s second quarter results were met with a positive market reaction as management highlighted the ongoing impact of its transformation strategy and disciplined cost management. CEO Marla Beck pointed to strong growth in consumables revenue, which now accounts for more than 70% of the business, as a central driver of improved margins. The launch of the HydraFillic with Pep9 booster and operational improvements contributed to gross margin gains and a reduction in operating expenses. However, Beck acknowledged that device sales continued to face pressure from broader macroeconomic headwinds, leading to a higher churn in the installed base than seen in previous quarters.

Is now the time to buy SKIN? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From BeautyHealth’s Q2 Earnings Call

• Allen Gong (JPMorgan) questioned the cautious third-quarter guidance despite recent momentum. CFO Michael Monahan explained this outlook reflected ongoing macro pressures, tariff impacts, and increased R&D spend, emphasizing a conservative approach to forecasting.
• Joseph Paul Federico (Stifel) asked about the step-down in EBITDA for the second half. Monahan attributed this to a combination of tariff headwinds, a shift to lower-margin refurbished device sales, and higher R&D investment for upcoming product launches.
• Oliver Chen (TD Securities) probed the outlook for device growth and the impact of macro factors versus internal execution. CEO Marla Beck responded that while the external environment is uncertain, new sales leadership and engagement programs are being implemented to drive device sales when conditions improve.
• Olivia Tong Cheang (Raymond James) inquired about the recent consumables price increase and its effect on demand and tariff coverage. Beck reported minimal negative feedback from providers, and Monahan noted the increase only partially offsets tariff costs.
• Sydney Wagner (Jefferies) sought detail on performance between provider channels. Beck highlighted growth in the nonmedical channel, with accessibly priced devices driving adoption, and strong booster uptake in the medical channel.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be watching (1) the pace of adoption for newly launched and upcoming consumables and skincare products, (2) the effectiveness of provider engagement and sales organization changes in driving device sales recovery, and (3) management’s ability to mitigate ongoing tariff and macroeconomic headwinds. Progress on the loyalty program relaunch and continued margin management will also be important indicators.

BeautyHealth currently trades at $2.45, up from $1.60 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.